LEADER 01575nam  2200433   450 
001 9910714981803321
005 20221102200834.0
035   $a(CKB)4100000011919708
035   $a(NjHacI)994100000011919708
035   $a(OCoLC)855729913
035   $a(EXLCZ)994100000011919708
100   $a20221102d2013      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aOral contraceptive use for the primary prevention of ovarian cancer /$fLaura J. Havrilesky [and thirteen others]
210  1$aRockville, MD :$cAgency for Healthcare Research and Quality (US),$d[2013]
210  4$dİ2013
215   $a1 online resource (514 pages) $cillustrations
225 1 $aEvidence reports/technology assessments ;$vNumber 212
300   $a"June 2013."
320   $aIncludes bibliographical references.
410  0$aEvidence report/technology assessment ;$vNumber 212.
606   $aOral contraceptives$xSide effects
606   $aOvaries$xCancer$xPrevention
615  0$aOral contraceptives$xSide effects.
615  0$aOvaries$xCancer$xPrevention.
676   $a613.9432
700   $aHavrilesky$b Laura J.$01353533
712 02$aUnited States.$bAgency for Healthcare Research and Quality,
712 02$aDuke University Evidence-based Practice Center.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910714981803321
996   $aOral contraceptive use for the primary prevention of ovarian cancer$93262525
997   $aUNINA